2020
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020DOI: 10.3310/hta24020
2019
Fleeman, N., Bagust, A., Duarte, R., Richardson, M., Nevitt, S., Boland, A., . . . Thorp, N. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(3), 293-302. doi:10.1007/s41669-018-0114-zDOI: 10.1007/s41669-018-0114-z
Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT (Journal article)
Bundred, N., Todd, C., Morris, J., Keeley, V., Purushotham, A., Bagust, A., . . . Riches, K. (2019). Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT.
2018
Bagust, A., & Beale, S. J. (2018). Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer. MEDICAL DECISION MAKING, 38(7), 789-796. doi:10.1177/0272989X18790966DOI: 10.1177/0272989X18790966
Stainthorpe, A., Greenhalgh, J., Bagust, A., Richardson, M., Boland, A., Beale, S., . . . Palmer, D. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36(10), 1153-1163. doi:10.1007/s40273-018-0646-1DOI: 10.1007/s40273-018-0646-1
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (Journal article)
Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3DOI: 10.1007/s40273-017-0592-3
2017
Fleeman, N., Bagust, A., Duarte, R., Chaplin, M., Nevitt, S., Boland, A., . . . Thorp, N. (n.d.). Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen (ID1072). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta515/documents/committee-papers
Fleeman, N., Bagust, A., Boland, A., Beale, S., Richardson, M., Krishan, A., . . . Payne, M. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35(10), 1035-1046. doi:10.1007/s40273-017-0504-6DOI: 10.1007/s40273-017-0504-6
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (Report)
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
Greenhalgh, J. (n.d.). Nab-paclitaxel with gemcitabine for 1st line metastatic pancreatic adenocarcinoma (ID1058). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (Report)
Greenhalgh, J., Bagust, A., Stainthorpe, A., Chaplin, M., Boland, A., De Sousa Rego Vieira Duarte, R., . . . Palmer, D. (2017). Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (14/90/01). NICE website. Retrieved from https://www.nice.org.uk/guidance/ta476/documents/committee-papers
2016
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
Greenhalgh, J. (n.d.). Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine (ID778). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta440/documents/committee-papers-2
Greenhalgh, J. (n.d.). Nivolumab for treating metastatic, non-squamous, non-small-cell lung cancer after chemotherapy (ID900). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta484/documents/committee-papers
Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2
2015
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2015). Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33(9), 893-904. doi:10.1007/s40273-015-0276-9DOI: 10.1007/s40273-015-0276-9
Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (Report)
Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. (Journal article)
Brown, T., Pilkington, G., Bagust, A., Boland, A., Oyee, J., Tudur Smith, C., . . . Dickson, R. (2015). Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 17(31), 281-282. doi:10.3310/hta17310-c201505DOI: 10.3310/hta17310-c201505
Ciclosporin for treating dry eye disease (Report)
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dwan, K., Kotas, E., . . . Ahmad, S. (2015). Ciclosporin for treating dry eye disease: Ciclosporin for treating dry eye disease (13/166/01). NICE Website. Retrieved from https://www.nice.org.uk/
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (Journal article)
Pilkington, G., Boland, A., Brown, T., Oyee, J., Bagust, A., & Dickson, R. (2015). A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. THORAX, 70, 359-367. doi:10.1136/thoraxjnl-2014-205914DOI: 10.1136/thoraxjnl-2014-205914
Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (Report)
Greenhalgh, J., Longworth, L., Crossan, C., Singh, J., Bagust, A., Boland, A., . . . Hall, M. (2015). Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: Edoxaban tosylate for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (14/14/01). NICE website. Retrieved from https://www.nice.org.uk/
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Oyee, J., Trevor, N., Beale, S., . . . O'Reilly, S. (2015). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics, 33(2), 137-148. doi:10.1007/s40273-014-0214-2DOI: 10.1007/s40273-014-0214-2
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Hockenhull, J., . . . Marshall, E. (2015). Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 19(47), I-133. doi:10.3310/hta19470DOI: 10.3310/hta19470
Fleeman, N., Bagust, A., Beale, S., Dwan, K., Dickson, R., Proudlove, C., & Dundar, Y. (2015). Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33(1), 13-23. doi:10.1007/s40273-014-0206-2DOI: 10.1007/s40273-014-0206-2
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290DOI: 10.3310/hta19290
2014
Fleeman, N., Bagust, A., Boland, A., Dwan, K., Chaplin, M., Beale, S., . . . Greystoke, A. (2014). Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer: Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer (13/106/01). NICE Website. Retrieved from https://www.nice.org.uk/
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (Report)
Greenhalgh, J., Bagust, A., Beale, S., Boland, A., Chaplin, M., Dwan, K., . . . Hall, M. (2014). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (14/15/01). NICE website. Retrieved from https://www.nice.org.uk/
Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (Report)
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history
Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach (Journal article)
Bagust, A., & Beale, S. (2014). Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach. MEDICAL DECISION MAKING, 34(3), 343-351. doi:10.1177/0272989X13497998DOI: 10.1177/0272989X13497998
2013
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal (Journal article)
Beale, S., Dickson, R., Bagust, A., Blundell, M., Dundar, Y., Boland, A., . . . Proudlove, C. (2013). Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. PHARMACOECONOMICS, 31(12), 1121-1129. doi:10.1007/s40273-013-0094-xDOI: 10.1007/s40273-013-0094-x
Description of health problem (Journal article)
Brown, T., Pilkington, G., Bagust, A., Boland, A., Oyee, J., Smith, C. T., . . . Dickson, R. (2013). Description of health problem. HEALTH TECHNOLOGY ASSESSMENT, 17(31), 1-+. doi:10.3310/hta17310DOI: 10.3310/hta17310
Bagust, A. (2013). Improving valuation sampling of EQ-5D health states.. Health and quality of life outcomes, 11, 14. doi:10.1186/1477-7525-11-14DOI: 10.1186/1477-7525-11-14
Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review (Journal article)
Brown, T., Pilkington, G., Boland, A., Oyee, J., Smith, C. T., Dundar, Y., . . . Dickson, R. (2013). Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 17(6), 1-+. doi:10.3310/hta17060DOI: 10.3310/hta17060
Erlotinib in monoterapia nel trattamento di mantenimento del carcinoma polmonare non a piccole cellule dopo chemioterapia a base di platino (Journal article)
Dickson, R., Bagust, A., Boland, A., Blundell, M., Davis, H., Dundar, Y., . . . Ramani, V. S. (2013). Erlotinib in monoterapia nel trattamento di mantenimento del carcinoma polmonare non a piccole cellule dopo chemioterapia a base di platino. PharmacoEconomics Italian Research Articles, 15(1), 35-44. doi:10.1007/s40276-013-0004-4DOI: 10.1007/s40276-013-0004-4
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Oyee, J., Beale, S., . . . Chu, P. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma A NICE Single Technology Appraisal. PHARMACOECONOMICS, 31(5), 403-413. doi:10.1007/s40273-013-0043-8DOI: 10.1007/s40273-013-0043-8
2011
Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal (Journal article)
Dickson, R., Bagust, A., Boland, A., Blundell, M., Davis, H., Dundar, Y., . . . Ramani, V. S. (2011). Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy A NICE Single Technology Appraisal. PHARMACOECONOMICS, 29(12), 1051-1062. doi:10.2165/11591600-000000000-00000DOI: 10.2165/11591600-000000000-00000
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Oyee, J., Blundell, M., . . . Fisher, M. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(31), 1-+. doi:10.3310/hta15310DOI: 10.3310/hta15310
Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE (Journal article)
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2011). Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. PharmacoEconomics Italian Research Articles, 13(2), 101-110. doi:10.1007/bf03320687DOI: 10.1007/bf03320687
Do cardiovascular patients with multivascular disease constitute an important clinical subgroup? Data from the CAPRIE trial (Journal article)
Greenhalgh, J., Boland, A., Bagust, A., Dickson, R., & Fisher, M. (2011). Do cardiovascular patients with multivascular disease constitute an important clinical subgroup? Data from the CAPRIE trial. European Heart Journal, 32, 231.
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis (Journal article)
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., . . . Thorp, N. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(42), 1-+. doi:10.3310/hta15420DOI: 10.3310/hta15420
Ticagrelor for the treatment of acute coronary syndromes: A Single Technology Appraisal (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Blundell, M., Lai, M., Dundar, Y., . . . Fisher, M. (2011). Ticagrelor for the treatment of acute coronary syndromes: A Single Technology Appraisal.
2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Brown, T., Boland, A., Bagust, A., Oyee, J., Hockenhull, J., Dundar, Y., . . . Proudlove, C. (2010). Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 71-79. doi:10.3310/hta14suppl2/10DOI: 10.3310/hta14suppl2/10
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal (Journal article)
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal. PHARMACOECONOMICS, 28(6), 439-448. doi:10.2165/11532220-000000000-00000DOI: 10.2165/11532220-000000000-00000
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes (Journal article)
Greenhalgh, J., Hockenhull, J., Rao, N., Dundar, Y., Dickson, R. C., & Bagust, A. (2010). Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5). doi:10.1002/14651858.CD004587.pub2DOI: 10.1002/14651858.CD004587.pub2
The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study (Journal article)
Sacco, J. J., Botten, J., Macbeth, F., Bagust, A., & Clark, P. (2010). The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study. PLOS ONE, 5(1). doi:10.1371/journal.pone.0008933DOI: 10.1371/journal.pone.0008933
Abatacept for the treatment of rheumatoid arthritis (Journal article)
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Fleeman, N., Kennedy, T., . . . Dickson, R. (2010). Abatacept for the treatment of rheumatoid arthritis. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/project/1648.asp
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07DOI: 10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05DOI: 10.3310/hta14suppl2/05
Pemetrexed for the treatment of relapsed non-small cell lung cancer (Journal article)
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Davis, H., Dickson, R., . . . Proudlove, N. (2010). Pemetrexed for the treatment of relapsed non-small cell lung cancer. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/erg/reports/1641.pdf
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05DOI: 10.3310/hta14suppl1/05
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. (Journal article)
Saborido, C. M., Hockenhull, J., Bagust, A., Boland, A., Dickson, R., & Todd, D. (2010). Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.. Health technology assessment (Winchester, England), 14(31), iii-75. doi:10.3310/hta14310DOI: 10.3310/hta14310
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation (Journal article)
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030DOI: 10.3310/hta14030
2009
Erlotinib for the treatment of relapsed non-small cell lung cancer (Journal article)
McLeod, C., Bagust, A., Boland, A., Hockenhull, J., Dundar, Y., Proudlove, C., . . . Dickson, R. (2009). Erlotinib for the treatment of relapsed non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 13, 41-47. doi:10.3310/hta13suppl1/07DOI: 10.3310/hta13suppl1/07
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (Journal article)
Dundar, Y., Bagust, A., Hounsome, J., McLeod, C., Boland, A., Davis, H., . . . Dickson, R. (2009). Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-28. doi:10.3310/hta13suppl1/04DOI: 10.3310/hta13suppl1/04
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. HEALTH TECHNOLOGY ASSESSMENT, 13, 49-54. doi:10.3310/hta13suppl3/08DOI: 10.3310/hta13suppl3/08
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation (Journal article)
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010DOI: 10.3310/hta13010
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. (Conference Paper)
Daemen, J., Simoons, M. L., Wijns, W., Bagust, A., Bos, G., Bowen, J. M., . . . Windecker, S. W. (2009). ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.. In European heart journal Vol. 30 (pp. 152-161). doi:10.1093/eurheartj/ehn510DOI: 10.1093/eurheartj/ehn510
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. (Conference Paper)
Daemen, J., Simoons, M. L., Wijns, W., Bagust, A., Bos, G., Bowen, J. M., . . . European Society of Cardiology. (2009). Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.. In EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology Vol. 4 (pp. 427-436). doi:10.4244/eijv4i4a75DOI: 10.4244/eijv4i4a75
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (Journal article)
Boland, A., Bagust, A., Hockenhull, J., Davis, H., Chu, P., & Dickson, R. (2009). Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. HEALTH TECHNOLOGY ASSESSMENT, 13, 41-48. doi:10.3310/hta13suppl2/06DOI: 10.3310/hta13suppl2/06
Rituximab for the treatment of rheumatoid arthritis (Journal article)
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-29. doi:10.3310/hta13suppl2/04DOI: 10.3310/hta13suppl2/04
2008
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation: Abstract (Journal article)
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Duendar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation: Abstract. HEALTH TECHNOLOGY ASSESSMENT, 12(12), 1-+. Retrieved from https://www.webofscience.com/
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. (Journal article)
Wolowacz, S. E., Cameron, D. A., Tate, H. C., & Bagust, A. (2008). Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(6), 925-933. doi:10.1200/jco.2006.10.4190DOI: 10.1200/jco.2006.10.4190
The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: A systematic review and economic evaluation (Journal article)
Hockenhull, J. C., Dwan, K., Boland, A., Smith, G., Bagust, A., Dündar, Y., . . . Dickson, R. (2008). The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: A systematic review and economic evaluation. Health Technology Assessment, 12(12). doi:10.3310/hta12120DOI: 10.3310/hta12120
2007
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes Mellitus in the UK (Journal article)
Home, P., Bagust, A., Taylor, M., Ambery, P., & da Costa, S. M. (2007). A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes Mellitus in the UK. PHARMACOECONOMICS, 25(9), 801-802. doi:10.2165/00019053-200725090-00008DOI: 10.2165/00019053-200725090-00008
Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. (Journal article)
Mount Hood 4 Modeling Group. (2007). Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.. Diabetes care, 30(6), 1638-1646. doi:10.2337/dc07-9919DOI: 10.2337/dc07-9919
Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. (Journal article)
Black, C., de Verteuil, R., Walker, S., Ayres, J., Boland, A., Bagust, A., & Waugh, N. (2007). Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature.. Thorax, 62(2), 131-138. doi:10.1136/thx.2006.064659DOI: 10.1136/thx.2006.064659
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. (Journal article)
McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., . . . Walley, T. (2007). Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.. Health technology assessment (Winchester, England), 11(28), 1-iv. doi:10.3310/hta11280DOI: 10.3310/hta11280
Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation (Journal article)
Dundar, Y., Bagust, A., Dickson, R., Dodd, S., Green, J., Haycox, A., . . . Walley, T. (2007). Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation. Health Technology Assessment, 11(1). doi:10.3310/hta11010DOI: 10.3310/hta11010
2006
'A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies' (Journal article)
Bagust, A., Evans, M., Beale, S., Home, P. D., Perry, A. S., & Stewart, M. (2006). 'A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies'. Pharmacoeconomics, 24(Supple), 5-19.
'Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK' (Journal article)
Beale, S., Bagust, A., Shearer, A. T., Martin, A., & Hulme, L. (2006). 'Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK'. Pharmacoeconomics, 24(Supple), 49-59.
'Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany' (Journal article)
Shearer, A. T., Bagust, A., Liebl, A., Schoeffski, O., & Goertz, A. (2006). 'Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany'. Pharmacoeconomics, 24(Supple), 20-34.
'Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain' (Journal article)
Shearer, A. T., Bagust, A., Ampudia-Blasco, F. J., Martinez-Lage Alvarez, B., Escolano, I. P., & Paris, G. (2006). 'Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain'. Pharmacoeconomics, 24(Supple), 35-48.
A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. (Journal article)
Bagust, A., Evans, M., Beale, S., Home, P. D., Perry, A. S., & Stewart, M. (2006). A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies.. PharmacoEconomics, 24 Suppl 1, 5-19. doi:10.2165/00019053-200624001-00002DOI: 10.2165/00019053-200624001-00002
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. (Journal article)
Bagust, A., Grayson, A. D., Palmer, N. D., Perry, R. A., & Walley, T. (2006). Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study.. Heart (British Cardiac Society), 92(1), 68-74. doi:10.1136/hrt.2004.053850DOI: 10.1136/hrt.2004.053850
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. (Journal article)
Shearer, A. T., Bagust, A., Ampudia-Blasco, F. J., Martínez-Lage Alvarez, B., Pérez Escolano, I., & París, G. (2006). Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.. PharmacoEconomics, 24 Suppl 1, 49-59. doi:10.2165/00019053-200624001-00005DOI: 10.2165/00019053-200624001-00005
The authors' reply (letter) (Journal article)
Bagust, A., Evans, M., Beale, S., Home, P., Perry, A., Stewart, M., . . . Paris, G. (2006). The authors' reply (letter). PharmacoEconomics, 24(9), 929-935. Retrieved from http://search.ebscohost.com/
The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: Systematic reviews (Journal article)
Black, C., Bagust, A., Boland, A., Walker, S., McLeod, C., De Verteuil, R., . . . Waugh, N. (2006). The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: Systematic reviews. Health Technology Assessment, 10(3). doi:10.3310/hta10030DOI: 10.3310/hta10030
2005
Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. (Journal article)
Bagust, A., & Beale, S. (2005). Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.. Health economics, 14(3), 217-230. doi:10.1002/hec.910DOI: 10.1002/hec.910
Guidelines for computer modeling of diabetes and its complications: response to American Diabetes Association Consensus Panel. (Journal article)
Bagust, A., & McEwan, P. (2005). Guidelines for computer modeling of diabetes and its complications: response to American Diabetes Association Consensus Panel.. Diabetes care, 28(2), 500. doi:10.2337/diacare.28.2.500DOI: 10.2337/diacare.28.2.500
'Coste-efectividad de la combinacion oral con rosiglitazona para la diabetes tipo 2: revision de aplicaciones de modelizacion europeas' (Journal article)
Shearer, A. T., Bagust, A., & Ampudia-Blasco, F. J. (2005). 'Coste-efectividad de la combinacion oral con rosiglitazona para la diabetes tipo 2: revision de aplicaciones de modelizacion europeas'. Avances en Diabetologia, 21(Supl.2), 99-107.
Randomized controlled trial to evaluate the clinical- and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses (Journal article)
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (2005). Randomized controlled trial to evaluate the clinical- and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. International Journal of Technology Assessment in Health Care, 21(1), 145-146. doi:10.1017/s0266462305230192DOI: 10.1017/s0266462305230192
2004
Exploring groups at high risk of restenosis (Journal article)
Bagust, A., Bakhai, A., Dickson, R., Dundar, Y., Hill, R. A., & Walley, T. (2004). Exploring groups at high risk of restenosis. EUROPEAN HEART JOURNAL, 25(23), 2168-2169. doi:10.1016/j.ehj.2004.09.028DOI: 10.1016/j.ehj.2004.09.028
Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK. (Journal article)
Shearer, A., Bagust, A., Sanderson, D., Heller, S., & Roberts, S. (2004). Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK.. Diabetic medicine : a journal of the British Diabetic Association, 21(5), 460-467. doi:10.1111/j.1464-5491.2004.01183.xDOI: 10.1111/j.1464-5491.2004.01183.x
Evaluating the performance of the Framingham risk equations in a population with diabetes. (Journal article)
McEwan, P., Williams, J. E., Griffiths, J. D., Bagust, A., Peters, J. R., Hopkinson, P., & Currie, C. J. (2004). Evaluating the performance of the Framingham risk equations in a population with diabetes.. Diabetic medicine : a journal of the British Diabetic Association, 21(4), 318-323. doi:10.1111/j.1464-5491.2004.01139.xDOI: 10.1111/j.1464-5491.2004.01139.x
'Pharmacoeconomics and Clinical Trials' (Chapter)
Haycox, A., & Bagust, A. (2004). 'Pharmacoeconomics and Clinical Trials'. In A. Haycox, T. Walley, & A. Boland (Eds.), 'Pharmacoeconomics' (pp. 127-140). Edinburgh: Churchill-Livingstone.
Coronary artery stents: a rapid systematic review and economic evaluation. (Journal article)
Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dündar, Y., Haycox, A., . . . Walley, T. (2004). Coronary artery stents: a rapid systematic review and economic evaluation.. Health technology assessment (Winchester, England), 8(35), iii-242. doi:10.3310/hta8350DOI: 10.3310/hta8350
Coronary artery stents:: a rapid systematic review and economic evaluation (Journal article)
Hill, R., Bagust, A., Bakhai, A., Dickson, R., Dündar, Y., Haycox, A., . . . Walley, T. (2004). Coronary artery stents:: a rapid systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 8(35), 1-+. Retrieved from https://www.webofscience.com/
Newer hypnotic drugs for the short-term management of insomnia:: a systematic review and economic evaluation (Journal article)
Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., . . . Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia:: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 8(24), 1-+. Retrieved from https://www.webofscience.com/
2003
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses (Journal article)
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (2003). A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment, 7(36).
Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry. (Journal article)
Strobl, J., Enzer, I., Bagust, A., Haycox, A., Smyth, R., Ashby, D., & Walley, T. (2003). Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry.. Pharmacoepidemiology and drug safety, 12(6), 467-473. doi:10.1002/pds.804DOI: 10.1002/pds.804
Early thrombosis for the treatment of acute myocardial infarction: A systematic review and economic evaluation (Journal article)
Boland, A., Dundar, Y., Bagust, A., Haycox, A., Hill, R., Mujica Mota, R., . . . Dickson, R. (2003). Early thrombosis for the treatment of acute myocardial infarction: A systematic review and economic evaluation. Health Technology Assessment, 7(15).
Deteriorating beta-cell function in type 2 diabetes: a long-term model. (Journal article)
Bagust, A., & Beale, S. (2003). Deteriorating beta-cell function in type 2 diabetes: a long-term model.. QJM : monthly journal of the Association of Physicians, 96(4), 281-288. doi:10.1093/qjmed/hcg040DOI: 10.1093/qjmed/hcg040
A model for costs of stroke services. (Journal article)
Sundberg, G., Bagust, A., & Terént, A. (2003). A model for costs of stroke services.. Health policy (Amsterdam, Netherlands), 63(1), 81-94. doi:10.1016/s0168-8510(02)00055-6DOI: 10.1016/s0168-8510(02)00055-6
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses (Journal article)
Boland, A., Haycox, A., Bagust, A., & Fitzsimmons, L. (n.d.). A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment, 7(36). doi:10.3310/hta7360DOI: 10.3310/hta7360
2002
Economic evaluation of an acute paediatric hospital at home clinical trial. (Journal article)
Bagust, A., Haycox, A., Sartain, S. A., Maxwell, M. J., & Todd, P. (2002). Economic evaluation of an acute paediatric hospital at home clinical trial.. Archives of disease in childhood, 87(6), 489-492. doi:10.1136/adc.87.6.489DOI: 10.1136/adc.87.6.489
Randomised controlled trial comparing an acute paediatric hospital at home scheme with conventional hospital care (Journal article)
Sartain, S. A., Maxwell, M. J., Todd, P. J., Jones, K. H., Bagust, A., Haycox, A., & Bundred, P. (2002). Randomised controlled trial comparing an acute paediatric hospital at home scheme with conventional hospital care. Archives of Disease in Childhood, 87(5), 371-375.
The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060. (Journal article)
Bagust, A., Hopkinson, P. K., Maslove, L., & Currie, C. J. (2002). The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060.. Diabetic medicine : a journal of the British Diabetic Association, 19 Suppl 4, 1-5. doi:10.1046/j.1464-5491.19.s4.2.xDOI: 10.1046/j.1464-5491.19.s4.2.x
2001
An economic model of the long-term health care burden of Type II diabetes. (Journal article)
Bagust, A., Hopkinson, P. K., Maier, W., & Currie, C. J. (2001). An economic model of the long-term health care burden of Type II diabetes.. Diabetologia, 44(12), 2140-2155. doi:10.1007/s001250100023DOI: 10.1007/s001250100023
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature (Journal article)
Hughes, D. A., Bagust, A., Haycox, A., & Walley, T. (2001). The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature. Health Economics, 10(7), 601-615.
Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study. (Journal article)
Macmillan, R. D., Barbera, D., Hadjiminas, D. J., Rampaul, R. S., Lee, A. H., Pinder, S. E., . . . Geraghty, J. G. (2001). Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study.. European journal of cancer (Oxford, England : 1990), 37(9), 1076-1080. doi:10.1016/s0959-8049(00)00367-1DOI: 10.1016/s0959-8049(00)00367-1
Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials. (Journal article)
Bagust, A., Barraza-Llorens, M., & Philips, Z. (2001). Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials.. European journal of cancer (Oxford, England : 1990), 37(9), 1081-1088. doi:10.1016/s0959-8049(01)00078-8DOI: 10.1016/s0959-8049(01)00078-8
Accounting for noncompliance in pharmacoeconomic evaluations (Journal article)
Hughes, D. A., Bagust, A., Haycox, A., & Walley, T. (2001). Accounting for noncompliance in pharmacoeconomic evaluations. PHARMACOECONOMICS, 19(12), 1185-1197. doi:10.2165/00019053-200119120-00001DOI: 10.2165/00019053-200119120-00001
2000
An integrated national pharmaceutical policy for the United Kingdom? (Journal article)
Walley, T., Earl-Slater, A., Haycox, A., & Bagust, A. (2000). An integrated national pharmaceutical policy for the United Kingdom?. BMJ (Clinical research ed.), 321(7275), 1523-1526. doi:10.1136/bmj.321.7275.1523DOI: 10.1136/bmj.321.7275.1523
An alternative to body mass index for standardizing body weight for stature. (Journal article)
Bagust, A., & Walley, T. (2000). An alternative to body mass index for standardizing body weight for stature.. QJM : monthly journal of the Association of Physicians, 93(9), 589-596. doi:10.1093/qjmed/93.9.589DOI: 10.1093/qjmed/93.9.589
1999
Cost of health care. The additional cost of obesity to the health service and the potential for resource savings from effective interventions (Journal article)
Bagust, A. (1999). Cost of health care. The additional cost of obesity to the health service and the potential for resource savings from effective interventions. The European Journal of Public Health, 9(4), 258-264. doi:10.1093/eurpub/9.4.258DOI: 10.1093/eurpub/9.4.258
Modelling Type 2 diabetes: A tool to aid medicine management (Conference Paper)
Bagust, A., Hopkinson, P. K., & Conway, P. (1999). Modelling Type 2 diabetes: A tool to aid medicine management. In Pharmaceutical Journal Vol. 263.
Dynamics of bed use in accommodating emergency admissions: stochastic simulation model. (Journal article)
Bagust, A., Place, M., & Posnett, J. W. (1999). Dynamics of bed use in accommodating emergency admissions: stochastic simulation model.. BMJ (Clinical research ed.), 319(7203), 155-158. doi:10.1136/bmj.319.7203.155DOI: 10.1136/bmj.319.7203.155
Importance of health economics must be recognised when trials are designed. (Journal article)
Haycox, A., Bagust, A., & Walley, T. (1999). Importance of health economics must be recognised when trials are designed.. BMJ (Clinical research ed.), 318(7199), 1696-1697. doi:10.1136/bmj.318.7199.1696aDOI: 10.1136/bmj.318.7199.1696a
Clinical guidelines-the hidden costs. (Journal article)
Haycox, A., Bagust, A., & Walley, T. (1999). Clinical guidelines-the hidden costs.. BMJ (Clinical research ed.), 318(7180), 391-393. doi:10.1136/bmj.318.7180.391DOI: 10.1136/bmj.318.7180.391
1997
Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. (Journal article)
Hendry, B. M., Viberti, G. C., Hummel, S., Bagust, A., & Piercy, J. (1997). Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.. QJM : monthly journal of the Association of Physicians, 90(4), 277-282. doi:10.1093/qjmed/90.4.277DOI: 10.1093/qjmed/90.4.277
An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom. (Journal article)
Hummel, S., Piercy, J., Wright, R., Davie, A., Bagust, A., & McMurray, J. (1997). An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United Kingdom.. PharmacoEconomics, 12(2 Pt 1), 182-192. doi:10.2165/00019053-199712020-00008DOI: 10.2165/00019053-199712020-00008
1996
League tables. (Journal article)
Bagust, A. (1996). League tables.. British journal of hospital medicine, 55(6), 369-370.
1992
Quality or quantity. (Journal article)
Bagust, A., Burrows, J., & Oakley, J. (1992). Quality or quantity.. The Health service journal, 102(5314), 23-25.
1991
The singers, not the song. (Journal article)
Burrows, J., Bagust, A., & Oakley, J. (1991). The singers, not the song.. The Health service journal, 101(5278), 24.
1990
Dispel that old myth. (Journal article)
Bagust, A. (1990). Dispel that old myth.. The Health service journal, 100(5208), 1000-1001.
1989
Modelling the implications for hospital services of cervical cytology screening: a case history. (Journal article)
Boyd, A., Davies, L. A., & Bagust, A. (1989). Modelling the implications for hospital services of cervical cytology screening: a case history.. The Journal of the Operational Research Society, 40(6), 529-537. doi:10.1057/jors.1989.90DOI: 10.1057/jors.1989.90
Resource management or managing resources? (Journal article)
Bagust, A. (1989). Resource management or managing resources?. Health services management research, 2(3), 217-220. doi:10.1177/095148488900200306DOI: 10.1177/095148488900200306
1988
Numbering the nurses. (Journal article)
Bagust, A., Prescott, J., & Smith, A. (1988). Numbering the nurses.. The Health service journal, 98(5108), 766-767.
